Aberdeen Wealth Management LLC Reduces Position in Zoetis Inc. (NYSE:ZTS)

Aberdeen Wealth Management LLC decreased its stake in Zoetis Inc. (NYSE:ZTS) by 3.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,443 shares of the company’s stock after selling 123 shares during the period. Aberdeen Wealth Management LLC’s holdings in Zoetis were worth $561,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Mission Wealth Management LP lifted its stake in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after acquiring an additional 59 shares during the period. VeraBank N.A. increased its holdings in Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after acquiring an additional 62 shares in the last quarter. HUB Investment Partners LLC increased its holdings in Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after acquiring an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC increased its holdings in Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock valued at $68,000 after acquiring an additional 64 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its stake in shares of Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after purchasing an additional 65 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $162.92 on Friday. The company has a market cap of $72.53 billion, a PE ratio of 29.78, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a fifty day moving average price of $156.48 and a two-hundred day moving average price of $164.84. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the previous year, the company posted $1.38 earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.23%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s payout ratio is currently 35.91%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ZTS shares. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus reduced their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research note on Monday, May 12th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $212.75.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.